Company Reports

Coloplast is a global manufacturer of intimate healthcare products and a market leader in ostomy, continence care, and voice and respiratory care, while holding smaller positions in wound care and interventional urology.

Coloplast is a global manufacturer of intimate healthcare products and a market leader in ostomy, continence care, and voice and respiratory care, while holding smaller positions in wound care and interventional urology.

Coloplast reported third-quarter fiscal 2026 results of 6% organic growth and 5% adjusted EBIT growth in constant currencies, reaching an adjusted EBIT margin of 26.2%. Management maintained full-year guidance of 5%-6% organic sales growth and 5% constant-currency EBIT growth.

We are transferring coverage of Coloplast to a new analyst. Coloplast is a global manufacturer of intimate healthcare products and the market leader in ostomy, continence care, and voice and respiratory care, with smaller positions in wound care and interventional urology.

Coloplast is a global manufacturer of intimate healthcare products and a market leader in ostomy, continence care, and voice and respiratory care, while holding smaller positions in wound care and interventional urology.

Coloplast reported fiscal second-quarter results that featured organic revenue and operating income both growing 6% year over year. Unfavorable foreign exchange and the Kerecis impairment charge of DKK 3 billion hampered earnings.

Coloplast posted fiscal first-quarter results showing 6% organic top-line growth and a 26% reported operating margin, but foreign exchange was a headwind. Shares fell by roughly 8%.

Based in Denmark, Coloplast is a leader in global ostomy and continence care. The firm has made inroads into the concentrated urology and fragmented woundcare markets, but it remains a peripheral player there. In contrast, Coloplast has a long record of consistent and meaningful innovation in ostomy and continence care that has led to a dominant position in Europe and steady growth in the US. Since 2008, the firm has done an admirable job of trimming its cost structure as it focused on profitable growth. After shifting the majority of its production to Hungary, China, and Costa Rica, Coloplast now enjoys a gross margin that beats that of rival Convatec by more than 1,150 basis points. Currently, Coloplast is altering its emphasis to enhance growth by entering new geographies, with an emphasis on the United States.

Coloplast faces new reimbursement challenges with the Medicare local coverage determination set to slash skin substitute payment rates in 2026, followed by the prospect of Medicare competitive bidding for ostomy and continence care supplies in 2028.

Coloplast reported fiscal fourth-quarter results that included 7% organic revenue growth, driven by 9% growth in both continence care and voice/respiratory. The firm also improved its operating margin by 220 basis points.

Coloplast saw fiscal third-quarter organic growth of 7%, but reported growth declined 1% thanks to the divestiture of the skin care business and unfavorable foreign exchange. Quarterly adjusted operating margin rose 100 basis points to 28% year over year.

Based in Denmark, Coloplast is a leader in global ostomy and continence care. The firm has made inroads into the concentrated urology and fragmented woundcare markets, but it remains a peripheral player there. In contrast, Coloplast has a long record of consistent and meaningful innovation in ostomy and continence care that has led to a dominant position in Europe and growth in the US. Since 2008, the firm has done an admirable job of trimming its cost structure as it focused on profitable growth. After shifting the majority of its production to Hungary, China, and Costa Rica, Coloplast now enjoys a gross margin that beats that of rival Convatec by more than 1,150 basis points. Currently, Coloplast is altering its emphasis to enhance growth by entering new geographies, with an emphasis on the United States.

Coloplast posted fiscal second-quarter performance that was fairly consistent with recent quarters as organic revenue rose 6% thanks to strength in continence care and advanced wound care. However, weakness in ostomy and interventional urology is likely to linger.

Coloplast announced that CEO Kristian Villumsen has stepped down from his role as of today. Former CEO Lars Rasmussen, who had been chair of the board, will become the interim CEO for the next 12 months as the board conducts a search.

Consistent with its long-term revenue growth profile, Coloplast delivered fiscal first-quarter top-line growth of 8%, though operating margin was held down at 27%.

The Centers for Medicare and Medicaid Services, or CMS, issued its final rule on the local coverage determination, or LCD, for skin substitutes and has included Coloplast's Kerecis (fish skin) for reimbursement.

Based in Denmark, Coloplast is a leader in global ostomy and continence care. The firm has made inroads into the concentrated urology and fragmented woundcare markets, but it remains a peripheral player there. In contrast, Coloplast has a long record of consistent and meaningful innovation in ostomy and continence care that has led to a dominant position in Europe and growth in the US. Since 2008, the firm has done an admirable job of trimming its cost structure as it focused on profitable growth. After shifting the majority of its production to Hungary, China, and Costa Rica, Coloplast now enjoys a gross margin that beats that of rival Convatec by more than 1,500 basis points. Currently, Coloplast is altering its emphasis to enhance growth by entering new geographies, with an emphasis on the United States.

Though inflationary pressures have been alleviated to some extent, Coloplast’s ongoing launches of key new products should damp operating margin until fiscal 2026. After taking another look at how these product introductions are going, we’re leaving our fair value estimate intact. Despite the incremental investment needed to support the commercialization of these new products, we think Coloplast’s advances in ostomy, continence care, and advanced wound technologies reinforce the foundation of the firm’s wide economic moat.

Based in Denmark, Coloplast is a leader in global ostomy and continence care. The firm has made inroads into the concentrated urology and fragmented woundcare markets, but it remains a peripheral player there. In contrast, Coloplast has a long record of consistent and meaningful innovation in ostomy and continence care that has led to a dominant position in Europe and growth in the US. Since 2008, the firm has done an admirable job of trimming its cost structure as it focused on profitable growth. After shifting the majority of its production to Hungary, China, and Costa Rica, Coloplast now enjoys a gross margin that beats that of rival Convatec by more than 1,500 basis points. Currently, Coloplast is altering its emphasis to enhance growth by entering new geographies, with an emphasis on the United States.

Coloplast delivered fiscal second-quarter results that held few surprises on the top and bottom lines. After slight adjustments for our near-term assumptions and revised share count, we’re leaving our fair value estimate unchanged. Organic quarterly revenue grew 8% year over year, which is consistent with Coloplast’s long-term pattern. However, operating margin remained under pressure thanks to inflation-influenced supplies and inventory, as well as the need to support key new product launches. With the firm in the early stages of commercializing several novel ostomy and continence care products, we remain confident in the firm’s wide economic moat.